{"id":35546,"date":"2015-10-27T13:25:30","date_gmt":"2015-10-27T12:25:30","guid":{"rendered":"https:\/\/blogs.bmj.com\/bmj\/?p=35546"},"modified":"2015-10-27T13:42:02","modified_gmt":"2015-10-27T12:42:02","slug":"diclectin-data-testing-canadas-new-pharmaceutical-transparency-law","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/","title":{"rendered":"Diclectin data: Testing Canada\u2019s new pharmaceutical transparency law"},"content":{"rendered":"

Earlier this month Canadian news sources, including the CBC<\/a> and the Toronto Star<\/a><\/em>, reported on Dr Navindra Persaud\u2019s success in securing unpublished data from Health Canada about the safety and effectiveness of Diclectin (a widely used treatment for nausea during pregnancy). To its credit, the country\u2019s drug regulator handed him thousands of pages of data from several clinical trials, including individual patient level data, in order for him to pursue his research. Yet it only did so after Dr Persaud signed a confidentiality agreement. The terms of that agreement provide an important test for Canada\u2019s newly enacted transparency law, since they may limit researchers\u2019 ability to meaningfully provide much needed scientific scrutiny of drug safety and effectiveness.<\/p>\n

In late 2014 Canada passed \u201cVanessa\u2019s Law<\/a>,\u201d creating several new powers, including the ability to recall drugs from the market and to enforce post-market pharmacovigilance study requirements. After\u00a0pressure from AllTrials<\/a> and others, Vanessa\u2019s Law was amended during the legislative process to include a requirement that drug companies make certain \u201cprescribed information\u201d (which has yet to be defined<\/a>) publicly available. The minister of health was also given the discretion to disclose \u201cconfidential business information\u201d to prevent drug related injuries or for the purposes of protecting or promoting human health or public safety.<\/p>\n

This new discretionary power in Vanessa\u2019s Law was used to share the Diclectin data with Dr Persaud. But Vanessa\u2019s Law says nothing about the terms under which that sharing can happen. So Health Canada filled in that legal void with this confidentiality agreement. It merits close scrutiny.<\/p>\n

Firstly, the agreement is strictly between Dr Persaud and Health Canada. Dr Persaud isn\u2019t allowed to share the data even with a colleague (say, a statistician) to help him complete the proposed analysis.<\/p>\n

Secondly, Dr Persaud agreed that the data he received would \u201cnot be reproduced in whole or in part in any document, paper, manuscript, etc. that [he] intends to publish or otherwise make public.\u201d He also has to destroy the information after the project is complete. This puts Dr Persaud in a catch 22 situation. The best practice<\/a> when publishing clinical studies is to make the underlying data publicly available. He needs access to the data to do his research. But in order to obtain the data he has to sign an agreement that prevents him from sharing them. Coupled with an inability to share data in the course of his research, this will significantly hamper scientific exchange of and constructive debate about the interpretation of the data.\u00a0Responsible scientists appreciate feedback in the process of data analysis, and expect data based challenges after publication.<\/p>\n

Thirdly, Dr Persaud is required to \u201cprovide Health Canada with a copy of any draft manuscript which was developed using the [data] at least 15 business days prior to submitting it for publication . . . in order for Health Canada to verify that the [data] was used for the purpose of the Project.\u201d This clause doesn\u2019t appear to give Health Canada the authority to veto publications at will. But the clause says nothing about how quickly Health Canada has to turn around study drafts or whether Dr Persaud can go ahead and submit after a reasonable timeframe. This provision could be used to delay publication\u2014which isn\u2019t hard to imagine if Dr Persaud finds, contrary to Health Canada\u2019s approval of the drug, that Diclectin is an ineffective treatment for morning sickness.<\/p>\n

How did Health Canada come up with these terms? Our guess is that they looked at the \u201cdata use agreements\u201d in place for other data sharing initiatives, such as\u00a0the Yale Open Data Access (YODA)<\/a> initiative and the model agreement set by companies participating in ClinicalStudyRequest.com<\/a>.<\/p>\n

There are some broad similarities between these agreements. Like the Persaud-Health Canada agreement, the YODA and model industry<\/a> agreements restrict use of the data to the specific research project proposed when seeking access to the data. The YODA and industry agreements also preclude researchers from sharing even de-identified data as part of a publication.<\/p>\n

But there are salient differences. On the positive side, the YODA agreements require researchers to provide a copy of publications as<\/em> they are submitted (not 15 days in advance like Health Canada). As well, both the YODA and industry agreements allow for at least some sharing of data for the purpose of carrying out the proposed research (think of the statistician).<\/p>\n

On the negative, the YODA and industry agreements require researchers to alert the companies involved (not regulators) of any safety concerns they identify, which could precipitate delayed safety warnings. Data from YODA and ClinicalStudyRequests.com must also be accessed through secure platforms, and not downloaded, which can impede efficient analysis<\/a>. Finally, it\u2019s clear that researchers have to provide detailed plans for their research, statistical analysis, etc. before<\/em> they can proceed (especially in the case of ClinicalStudyRequests.com), which has the potential to undermine the level of independent scrutiny<\/a> that researchers who obtain data access are able to provide.<\/p>\n

Even if the Persaud-Health Canada agreement is comparable to the YODA and model industry agreements, the fundamental question is why these agreements should become the standard? Health Canada could have instead looked at the \u201cTerms of Use\u201d (ToU) of the European Medicines Agency\u2019s (EMA’s) new\u00a0clinical data publication policy<\/a>. The EMA\u2019s ToU provide access to data for research purposes without any imposition of confidentiality with regards to the data\u2014either during the research process or for the purpose of publication. Researchers have to confirm their identity and the purpose of the research. They also have to agree not to \u201cre-identify\u201d clinical trial participants or use the data for \u201ccommercial purposes.\u201d But their use of the data for research, including comparative effectiveness research<\/a>, is otherwise unfettered.<\/p>\n

If the goal of the transparency powers in Vanessa\u2019s Law is to encourage independent scrutiny of drug safety and effectiveness data, thereby contributing to a better protection of the public, Health Canada can and must do better. The focus must be on facilitating Dr Persaud and others like him to analyze the data in order to protect or promote human health and the safety of the public. Instead, Health Canada\u2019s approach appears to make that harder to achieve. The legal warning that the agency will \u201cclosely monitor compliance\u201d and take \u201clegal action in the event of the breach\u201d\u2014a point stressed in an accompanying letter to Dr Persaud\u2014can also hardly be seen as encouraging independent scrutiny.<\/p>\n

If Health Canada is really committed to transparency, it should exclude drug safety and effectiveness data from the scope of \u201cconfidential business information\u201d (which some of us argued for<\/a> while Vanessa\u2019s Law went through the legislative process). Had it done so already with the data Dr Persaud requested, Canada\u2019s drug regulator could have focused on how to allow publication of the findings and underlying data, while protecting research participants\u2019 privacy through de-identification. With the imposition of its confidentiality agreement, it has imposed excessive secrecy and requested destruction of the data once the research is complete\u2014all under threat of liability.<\/p>\n

\"Matthew_Herder_headshot\"<\/a>Matthew Herder<\/strong>, assistant professor, Health Law Institute, Faculties of Medicine and Law, Dalhousie University. Twitter: @cmrherder<\/a><\/em><\/p>\n

Competing interests: MH is a member of the Health Policy Translation research group of the Canadian Center for Vaccinology (CCfV), which has carried out a number of clinical trials sponsored by vaccine manufacturers. MH has not been involved, in any way, with the conduct of these trials, nor received any funds from CCfV to carry out research. He has no other personal, organization, or relational conflicts of interest to disclose.<\/p>\n

\"\"<\/a>
\nTrudo Lemmens<\/strong>, professor and scholl chair in health law and policy, Faculties of Law and Public Health and Joint Centre for Bioethics, University of Toronto. Twitter: @TrudoLemmens<\/a><\/em><\/p>\n

Competing interests: None declared.<\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Earlier this month Canadian news sources, including the CBC and the Toronto Star, reported on Dr Navindra Persaud\u2019s success in securing unpublished data from Health Canada about the safety and […]<\/p>\n

More…<\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5744],"tags":[],"class_list":["post-35546","post","type-post","status-publish","format-standard","hentry","category-open-data"],"yoast_head":"\nDiclectin data: Testing Canada\u2019s new pharmaceutical transparency law - The BMJ<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Diclectin data: Testing Canada\u2019s new pharmaceutical transparency law - The BMJ\" \/>\n<meta property=\"og:description\" content=\"Earlier this month Canadian news sources, including the CBC and the Toronto Star, reported on Dr Navindra Persaud\u2019s success in securing unpublished data from Health Canada about the safety and [...]More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/\" \/>\n<meta property=\"og:site_name\" content=\"The BMJ\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/bmjdotcom\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-10-27T12:25:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2015-10-27T12:42:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/bmj\/files\/2015\/10\/Matthew_Herder_headshot.jpg\" \/>\n<meta name=\"author\" content=\"BMJ\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:site\" content=\"@bmj_latest\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"BMJ\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/\"},\"author\":{\"name\":\"BMJ\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\"},\"headline\":\"Diclectin data: Testing Canada\u2019s new pharmaceutical transparency law\",\"datePublished\":\"2015-10-27T12:25:30+00:00\",\"dateModified\":\"2015-10-27T12:42:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/\"},\"wordCount\":1306,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2015\\\/10\\\/Matthew_Herder_headshot.jpg\",\"articleSection\":[\"Open data\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/\",\"name\":\"Diclectin data: Testing Canada\u2019s new pharmaceutical transparency law - The BMJ\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2015\\\/10\\\/Matthew_Herder_headshot.jpg\",\"datePublished\":\"2015-10-27T12:25:30+00:00\",\"dateModified\":\"2015-10-27T12:42:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2015\\\/10\\\/Matthew_Herder_headshot.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2015\\\/10\\\/Matthew_Herder_headshot.jpg\",\"width\":199,\"height\":209},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/2015\\\/10\\\/27\\\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Diclectin data: Testing Canada\u2019s new pharmaceutical transparency law\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"name\":\"The BMJ\",\"description\":\"Helping doctors make better decisions.\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#organization\",\"name\":\"The BMJ\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/files\\\/2018\\\/05\\\/The-BMJ-logo.jpg\",\"width\":852,\"height\":568,\"caption\":\"The BMJ\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/bmjdotcom\\\/\",\"https:\\\/\\\/x.com\\\/bmj_latest\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/#\\\/schema\\\/person\\\/ba3da426ed20e8f1d933ca367d8216fe\",\"name\":\"BMJ\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g\",\"caption\":\"BMJ\"},\"sameAs\":[\"https:\\\/\\\/blogs.bmj.com\\\/\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/bmj\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Diclectin data: Testing Canada\u2019s new pharmaceutical transparency law - The BMJ","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/","og_locale":"en_US","og_type":"article","og_title":"Diclectin data: Testing Canada\u2019s new pharmaceutical transparency law - The BMJ","og_description":"Earlier this month Canadian news sources, including the CBC and the Toronto Star, reported on Dr Navindra Persaud\u2019s success in securing unpublished data from Health Canada about the safety and [...]More...","og_url":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/","og_site_name":"The BMJ","article_publisher":"https:\/\/www.facebook.com\/bmjdotcom\/","article_published_time":"2015-10-27T12:25:30+00:00","article_modified_time":"2015-10-27T12:42:02+00:00","og_image":[{"url":"https:\/\/blogs.bmj.com\/bmj\/files\/2015\/10\/Matthew_Herder_headshot.jpg","type":"","width":"","height":""}],"author":"BMJ","twitter_card":"summary_large_image","twitter_creator":"@bmj_latest","twitter_site":"@bmj_latest","twitter_misc":{"Written by":"BMJ","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/"},"author":{"name":"BMJ","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe"},"headline":"Diclectin data: Testing Canada\u2019s new pharmaceutical transparency law","datePublished":"2015-10-27T12:25:30+00:00","dateModified":"2015-10-27T12:42:02+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/"},"wordCount":1306,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2015\/10\/Matthew_Herder_headshot.jpg","articleSection":["Open data"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/","url":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/","name":"Diclectin data: Testing Canada\u2019s new pharmaceutical transparency law - The BMJ","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2015\/10\/Matthew_Herder_headshot.jpg","datePublished":"2015-10-27T12:25:30+00:00","dateModified":"2015-10-27T12:42:02+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/#primaryimage","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2015\/10\/Matthew_Herder_headshot.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2015\/10\/Matthew_Herder_headshot.jpg","width":199,"height":209},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/bmj\/2015\/10\/27\/diclectin-data-testing-canadas-new-pharmaceutical-transparency-law\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/bmj\/"},{"@type":"ListItem","position":2,"name":"Diclectin data: Testing Canada\u2019s new pharmaceutical transparency law"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/bmj\/#website","url":"https:\/\/blogs.bmj.com\/bmj\/","name":"The BMJ","description":"Helping doctors make better decisions.","publisher":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/bmj\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/bmj\/#organization","name":"The BMJ","url":"https:\/\/blogs.bmj.com\/bmj\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","contentUrl":"https:\/\/blogs.bmj.com\/bmj\/files\/2018\/05\/The-BMJ-logo.jpg","width":852,"height":568,"caption":"The BMJ"},"image":{"@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/bmjdotcom\/","https:\/\/x.com\/bmj_latest"]},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/bmj\/#\/schema\/person\/ba3da426ed20e8f1d933ca367d8216fe","name":"BMJ","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b4d8f39281bcae118348a1c027347b8e53b82d42520e774a8b50dd9a6ac6c01d?s=96&d=mm&r=g","caption":"BMJ"},"sameAs":["https:\/\/blogs.bmj.com\/"],"url":"https:\/\/blogs.bmj.com\/bmj\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/35546","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/comments?post=35546"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/posts\/35546\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/media?parent=35546"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/categories?post=35546"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/bmj\/wp-json\/wp\/v2\/tags?post=35546"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}